One is Compendia Bioscience, an Ann Arbor, Mich., computational biotech that’s focused on mining cancer-genomics data. The company just received a $2.4 million grant from the National Cancer Institute to further development of Compendia’s lead product, a program that combs through and analyzes publicly available data on gene activity in a variety of tumors. David Hamilton at VentureBeat LifeSciences has more about "gene chips," etc, here.